Hope rises for cancer treatment as key drug gets U.S. approval

Drugs used to illustrate the story.

The U.S. Food and Drug Administration (FDA) on Wednesday granted breakthrough therapy designation to drug maker, AstraZeneca’s biggest new drug hope Durvalumab for the treatment in bladder cancer.

The experimental medicine is a “PD-L1’’ therapy that fights cancer by boosting the immune system.

The breakthrough therapy designation expedites the development and review of medicines intended to treat serious or life-threatening diseases.

The drug, Durvalumab, is also being developed as a treatment for lung, head and neck, gastric, pancreatic, liver and blood cancers.

The drug is competing with rival products made by Bristol-Myers Squibb, Merck and Roche.



Now available on

  Premium Times Android mobile applicationPremium Times iOS mobile applicationPremium Times blackberry mobile applicationPremium Times windows mobile application

TEXT AD: Revealed!!! The Only Way Left of Getting an Extra Large Manhood and also Last Up to 38Mins+. Get the Insider Secret Here

All rights reserved. This material and any other material on this platform may not be reproduced, published, broadcast, written or distributed in full or in part, without written permission from PREMIUM TIMES.

  • aisha ani

    Basically means the drug is on fast track to being approved, unfortunately some of these drugs cost about $5000 for a month’s therapy. I pray Nigeria will get here one day, until then one would hope the rich folks will set up foundations to help the less privileged.

  • FormerlyAPC

    I’m happy that Premium Times can pick up such important news item. Coincidentally, at my place of work, application was being sought for the same drug, for the treatment of other types of cancer. Can NAFDAC and Nigerian Government make it possible for NIgerians abroad who have the expertise to develop or are reviewing and regulating new drugs come and give a helping hand?